Brazil plans to buy 60 million doses of the single-shot COVID-19 vaccine developed by China's CanSino Biologics for delivery in the third and fourth quarters of this year, Reuters news agency reported on Wednesday.
According to a negotiation document reviewed by Reuters, a ministry official signed a letter of intent on 4 June 2021 to purchase the vaccine doses with Belcher Farmaceutica do Brasil, a Brazilian pharmaceutical company that represents CanSino in Brazil.
This vaccine, trade-named Convidecia and developed by CanSino together with a research institute linked to the Chinese military, will cost USD17 per dose, the document said.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma